<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012470</article-id><article-id pub-id-type="publisher-id">ACM-39433</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_40093455.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  三阴性乳腺癌患者化疗后血糖血脂代谢状况及其影响因素的分析
  The Metabolism of Blood Glucose and Lipid and Its Influence Factors Analysis in Triple-Negative Breast Cancer Patients after Chemotherapy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>臧</surname><given-names>龙龙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>程</surname><given-names>敬敬</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>韬</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>红军</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛；青岛大学附属医院肿瘤科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院肿瘤科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3142</fpage><lpage>3150</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探究三阴性乳腺癌(TNBC)患者首次接受标准方案化疗前和化疗后血糖血脂代谢状况的差异，并分析其影响因素。方法：回顾性收集2013年1月~2020年1月年期间就诊于青岛大学附属医院并首次接受化疗治疗的TNBC患者。通过检测患者化疗前、后血糖血脂水平，分析血糖血脂代谢状况的变化及其影响因素。结果：251例TNBC患者，化疗前、化疗后中位血糖水平分别为：5.13 mmol/L、5.59 mmol/L；化疗前、化疗后中位总胆固醇(TC)水平分别为：5.17 mmol/L、5.64 mmol/L；化疗前、化疗后中位低密度脂蛋白(LDL)水平分别为：3.00 mmol/L、3.34 mmol/L；差异均有统计学意义(P &lt; 0.05)。是否绝经与化疗后血糖、TC和LDL代谢相关。不同化疗方式、化疗方案以及化疗周期长短与化疗后患者的血糖血脂水平相关(P &lt; 0.05)。结论：TNBC患者首次接受标准方案化疗后可出现血糖、血脂代谢紊乱，需要关注TNBC患者化疗后增加的罹患心血管疾病潜在的风险。
    Objective: To analyze the difference of blood glucose and lipid metabolism in triple-negative breast cancer (TNBC) patients after chemotherapy with standard regimens for the first time, and to analyze its influencing factors to provide evidence for monitoring cardiovascular risk factors in TNBC patients after chemotherapy. Methods: From January 2013 to January 2020, TNBC patients who were admitted to the Affiliated Hospital of Qingdao University and received chemotherapy for the first time were collected. By monitoring the blood glucose and lipid levels before and after chemotherapy, the changes of blood glucose and lipid metabolism and its influencing factors are analyzed. Results: 251 TNBC patients were enrolled. The median blood glucose levels before chemotherapy were 5.13 mmol/L, lower than 5.59 mmol/L after chemotherapy (P &lt; 0.05). The median total cholesterol (TC) levels before chemotherapy were 5.17 mmol/L, lower than 5.64 mmol/L after chemotherapy (P &lt; 0.05). The median low-density lipoprotein (LDL) levels before chemotherapy were 3.00 mmol/L, lower than 3.34 mmol/L after chemotherapy (P &lt; 0.05). The menopausal status of patients is related to blood glucose, TC and LDL metabolism. Different chemotherapy methods, chemotherapy regimens and the length of the chemotherapy cycle are related to the blood glucose and blood lipid levels (P &lt; 0.05). Conclusion: TNBC patients may have blood glucose and lipid metabolism disorders after receiving standard chemotherapy for the first time. It is necessary to pay attention to the increased potential risk of cardiovascular disease in TNBC patients after chemotherapy. 
  
 
</p></abstract><kwd-group><kwd>三阴性乳腺癌，化疗，血糖，血脂, Triple-Negative Breast Cancer</kwd><kwd> Chemotherapy</kwd><kwd> Blood Glucose</kwd><kwd> Blood Lipid</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探究三阴性乳腺癌(TNBC)患者首次接受标准方案化疗前和化疗后血糖血脂代谢状况的差异，并分析其影响因素。方法：回顾性收集2013年1月~2020年1月年期间就诊于青岛大学附属医院并首次接受化疗治疗的TNBC患者。通过检测患者化疗前、后血糖血脂水平，分析血糖血脂代谢状况的变化及其影响因素。结果：251例TNBC患者，化疗前、化疗后中位血糖水平分别为：5.13 mmol/L、5.59 mmol/L；化疗前、化疗后中位总胆固醇(TC)水平分别为：5.17 mmol/L、5.64 mmol/L；化疗前、化疗后中位低密度脂蛋白(LDL)水平分别为：3.00 mmol/L、3.34 mmol/L；差异均有统计学意义(P &lt; 0.05)。是否绝经与化疗后血糖、TC和LDL代谢相关。不同化疗方式、化疗方案以及化疗周期长短与化疗后患者的血糖血脂水平相关(P &lt; 0.05)。结论：TNBC患者首次接受标准方案化疗后可出现血糖、血脂代谢紊乱，需要关注TNBC患者化疗后增加的罹患心血管疾病潜在的风险。</p></sec><sec id="s2"><title>关键词</title><p>三阴性乳腺癌，化疗，血糖，血脂</p></sec><sec id="s3"><title>The Metabolism of Blood Glucose and Lipid and Its Influence Factors Analysis in Triple-Negative Breast Cancer Patients after Chemotherapy</title><p>Longlong Zang<sup>1,2</sup>, Jingjing Cheng<sup>2</sup>, Tao Jiang<sup>2</sup>, Hongjun Zhang<sup>2*</sup></p><p><sup>1</sup>Medical Department, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/40-1571784x5_hanspub.png" /></p><p>Received: Nov. 21<sup>st</sup>, 2020; accepted: Dec. 21<sup>st</sup>, 2020; published: Dec. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/40-1571784x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the difference of blood glucose and lipid metabolism in triple-negative breast cancer (TNBC) patients after chemotherapy with standard regimens for the first time, and to analyze its influencing factors to provide evidence for monitoring cardiovascular risk factors in TNBC patients after chemotherapy. Methods: From January 2013 to January 2020, TNBC patients who were admitted to the Affiliated Hospital of Qingdao University and received chemotherapy for the first time were collected. By monitoring the blood glucose and lipid levels before and after chemotherapy, the changes of blood glucose and lipid metabolism and its influencing factors are analyzed. Results: 251 TNBC patients were enrolled. The median blood glucose levels before chemotherapy were 5.13 mmol/L, lower than 5.59 mmol/L after chemotherapy (P &lt; 0.05). The median total cholesterol (TC) levels before chemotherapy were 5.17 mmol/L, lower than 5.64 mmol/L after chemotherapy (P &lt; 0.05). The median low-density lipoprotein (LDL) levels before chemotherapy were 3.00 mmol/L, lower than 3.34 mmol/L after chemotherapy (P &lt; 0.05). The menopausal status of patients is related to blood glucose, TC and LDL metabolism. Different chemotherapy methods, chemotherapy regimens and the length of the chemotherapy cycle are related to the blood glucose and blood lipid levels (P &lt; 0.05). Conclusion: TNBC patients may have blood glucose and lipid metabolism disorders after receiving standard chemotherapy for the first time. It is necessary to pay attention to the increased potential risk of cardiovascular disease in TNBC patients after chemotherapy.</p><p>Keywords:Triple-Negative Breast Cancer, Chemotherapy, Blood Glucose, Blood Lipid</p><disp-formula id="hanspub.39433-formula39"><graphic xlink:href="//html.hanspub.org/file/40-1571784x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/40-1571784x8_hanspub.png" /> <img src="//html.hanspub.org/file/40-1571784x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>乳腺癌是女性最常见的恶性肿瘤之一，三阴性乳腺癌(TNBC)作为乳腺癌一种特殊的临床亚型，指雌激素受体、孕激素受体和人表皮生长因子受体2 (Her-2)均不表达的乳腺癌，约占所有乳腺癌的15% [<xref ref-type="bibr" rid="hanspub.39433-ref1">1</xref>]，细胞分化差，具有高度的侵袭性，易复发和转移 [<xref ref-type="bibr" rid="hanspub.39433-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref3">3</xref>]。目前针对TNBC的治疗方法单一，患者对以抗Her-2为主的靶向治疗以及内分泌治疗不敏感，多药联合化疗是常用的治疗方案，化疗对改善TNBC患者的生存具有重要作用 [<xref ref-type="bibr" rid="hanspub.39433-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref5">5</xref>]。以乳腺癌为代表的多种女性好发恶性肿瘤，与心血管系统疾病有许多共同的病因和危险因素，例如高血糖、高血脂和肥胖等 [<xref ref-type="bibr" rid="hanspub.39433-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref7">7</xref>]，随着检查和治疗手段的进步，乳腺癌患者的生存期得到不断延长，接受手术及化疗后获得长期生存的乳腺癌患者面临的心血管系统疾病风险也在不断增加。有研究显示化疗对乳腺癌患者的血糖血脂代谢产生一定的影响，但报道的结果存在差异 [<xref ref-type="bibr" rid="hanspub.39433-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref10">10</xref>]。TNBC因其治疗手段的局限性，多药联合化疗是主要治疗方案，目前化疗对TNBC患者血糖血脂代谢状况的影响尚不明确，化疗可能通过直接损伤心肌细胞以及改变患者血糖血脂代谢的方式，导致心血管系统患病风险的增加，接受化疗的患者可能会出现继发于化疗的潜在心血管系统效应。因此，探究TNBC患者首次接受标准疗程化疗前、后血糖血脂指标水平的变化，分析影响血糖、血脂变化的因素，有可能为监测并降低TNBC患者化疗后罹患心血管系统疾病的风险提供依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><p>1) 回顾性的选取2013年1月~2020年1月期间于青岛大学附属医院就诊并经病理学及免疫组化确诊的三阴性乳腺癌(TNBC)患者251例，年龄范围24~75岁，平均年龄为54岁。纳入标准：1. 均为女性，2. 患者均为首次接受抗肿瘤治疗，且按标准治疗完成化疗。排除标准：排除严重心、肝、肾等系统性疾病及合并其他恶性肿瘤的患者。研究已获得青岛大学附属医院伦理委员会批准。患者临床病理学特征见表1。</p><p>2) 根据患者一般情况及临床特点，合理选择手术治疗后行辅助化疗、新辅助化疗后行手术治疗或行姑息性化疗。化疗方案选择、剂量及用法参考《中国抗癌协会乳腺癌诊治指南与规范》，治疗方案包括：AT (蒽环类联合紫杉类)、FEC-T (氟尿嘧啶 + 蒽环类 + 环磷酰胺序贯紫杉类)、AC-T (蒽环类 + 环磷酰胺序贯紫杉类)、TC (紫杉类联合环磷酰胺)、TAC (紫杉类 + 蒽环类 + 环磷酰胺)、其他方案。病理组织学分类按照WHO组织学分类，根据AJCC乳腺癌分期标准(第7版)进行临床分期，术后患者按照组织学病理结果进行TNM分期 [<xref ref-type="bibr" rid="hanspub.39433-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref12">12</xref>]。</p><p>3) 采集患者化疗前和标准疗程化疗后的血液学标本，进行血糖、血脂水平的检测。检测参考标准：血糖：3.90~6.16 mmol/L；总胆固醇(TC)：2.32~5.62 mmol/L；甘油三酯(TG)：0.30~1.92 mmol/L；低密度脂蛋白(LDL)：1.90~3.12 mmol/L；高密度脂蛋白(HDL)：0.80~2.35 mmol/L [<xref ref-type="bibr" rid="hanspub.39433-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref14">14</xref>]。</p><p>4) 统计学方法：采用SPSS 21.0软件进行统计学分析，χ<sup>2</sup>检验用于比较组间差异，非参数秩和检验计量资料，P &lt; 0.05认为具有统计学差异。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinicopathological characteristics of 251 patient</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >临床病理特征</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >百分比(%)</th></tr></thead><tr><td align="center" valign="middle" >月经状态</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >绝经</td><td align="center" valign="middle" >163</td><td align="center" valign="middle" >65</td></tr><tr><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >35</td></tr><tr><td align="center" valign="middle" >病理类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >浸润性导管癌</td><td align="center" valign="middle" >208</td><td align="center" valign="middle" >82.9</td></tr><tr><td align="center" valign="middle" >浸润性小叶癌</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >髓样癌</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >体质指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;18.5</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.4</td></tr><tr><td align="center" valign="middle" >18.5~23.9</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >39.8</td></tr><tr><td align="center" valign="middle" >≥24</td><td align="center" valign="middle" >145</td><td align="center" valign="middle" >57.8</td></tr><tr><td align="center" valign="middle" >临床分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I期</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >31.9</td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" >122</td><td align="center" valign="middle" >48.6</td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >15.9</td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3.6</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >化疗方式</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >辅助化疗</td><td align="center" valign="middle" >216</td><td align="center" valign="middle" >86.1</td></tr><tr><td align="center" valign="middle" >新辅助化疗</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >姑息化疗</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3.6</td></tr><tr><td align="center" valign="middle" >化疗方案</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >AT</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.8</td></tr><tr><td align="center" valign="middle" >FEC-T</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >6.4</td></tr><tr><td align="center" valign="middle" >AC-T</td><td align="center" valign="middle" >193</td><td align="center" valign="middle" >76.9</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >5.1</td></tr><tr><td align="center" valign="middle" >TAC</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >4.4</td></tr><tr><td align="center" valign="middle" >其他方案</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >4.4</td></tr><tr><td align="center" valign="middle" >化疗周期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤4周期</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >4~8周期</td><td align="center" valign="middle" >203</td><td align="center" valign="middle" >80.9</td></tr><tr><td align="center" valign="middle" >≥8周期</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >13.1</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 251例患者临床病理学特征</p></sec><sec id="s7"><title>3. 结果</title><p>1) TNBC患者化疗前、后血液学检验指标水平的比较(表2)：患者化疗前、化疗后中位血糖水平分别为：5.13 mmol/L、5.59 mmol/L；化疗前、后中位TC水平分别为：5.17 mmol/L、5.64 mmol/L；化疗前、后中位LDL水平分别为：3.00 mmol/L、3.34 mmol/L；差异均具有统计学意义(P &lt; 0.05)。化疗后TG和HDL水平与化疗前相比，差异无统计学意义(P &gt; 0.05)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The difference in blood glucose and lipid levels of 51 triple-negative breast cancer patients before and after chemotherap</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >检验项目</th><th align="center" valign="middle"  colspan="2"  >血液学指标水平</th><th align="center" valign="middle"  rowspan="2"  >χ<sup>2</sup></th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >正常(例)</td><td align="center" valign="middle" >异常(例)</td></tr><tr><td align="center" valign="middle" >血糖</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >48.996</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >222</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >154</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8.803</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >157</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >124</td><td align="center" valign="middle" >127</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.183</td><td align="center" valign="middle" >0.074</td></tr><tr><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >183</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >LDL</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16.474</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >130</td><td align="center" valign="middle" >121</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >166</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >HDL</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.580</td><td align="center" valign="middle" >0.447</td></tr><tr><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >246</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >249</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 251例三阴性乳腺癌患者化疗前、后血糖血脂水平的差异</p><p>2) TNBC患者临床病理学特征与化疗前、后血液学检测指标的关系：化疗前(表3)，已绝经和未绝经患者的中位血糖、TC、TG、LDL和HDL水平差异均具有统计学意义(P &lt; 0.05)。体质指数 &lt; 18.5 kg/m<sup>2</sup>、18.5~23.9 kg/m<sup>2</sup>、≥24 kg/m<sup>2</sup>患者的中位血糖和中位TG水平差异具有统计学意义(P &lt; 0.05)。组织学类型与患者的中位TC和LDL水平差异相关(P &lt; 0.05)，与血糖、TG和HDL代谢无关(P &gt; 0.05)，临床分期与患者的各项检验指标水平差异均无关(P &gt; 0.05)。</p><p>化疗后(表4)，已绝经和未绝经患者的中位血糖、TC和LDL水平差异具有统计学意义(P &lt; 0.05)。体质指数 &lt; 18.5 kg/m<sup>2</sup>、18.5~23.9 kg/m<sup>2</sup>、≥24 kg/m<sup>2</sup>患者的血糖、TC和HDL水平差异具有统计学意义(P &lt; 0.05)。组织学类型与患者的中位TC水平差异相关(P &lt; 0.05)，与血糖、TG、LDL和HDL代谢无关(P &gt; 0.05)，临床分期与患者的各项检验指标水平差异均无关(P &gt; 0.05)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The relationship between clinicopathological characteristics and median blood glucose and lipid levels before chemotherap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床特征</th><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >血糖</th><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle" >LDL</th><th align="center" valign="middle" >HDL</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >月经状态</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >4.92</td><td align="center" valign="middle" >4.62</td><td align="center" valign="middle" >1.07</td><td align="center" valign="middle" >2.66</td><td align="center" valign="middle" >1.40</td></tr><tr><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >5.20</td><td align="center" valign="middle" >5.43</td><td align="center" valign="middle" >1.35</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >1.50</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.026</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >体质指数</td><td align="center" valign="middle" >&lt;18.5</td><td align="center" valign="middle" >4.74</td><td align="center" valign="middle" >5.17</td><td align="center" valign="middle" >0.95</td><td align="center" valign="middle" >2.96</td><td align="center" valign="middle" >1.45</td></tr><tr><td align="center" valign="middle" >18.5~23.9</td><td align="center" valign="middle" >4.96</td><td align="center" valign="middle" >5.18</td><td align="center" valign="middle" >1.05</td><td align="center" valign="middle" >2.92</td><td align="center" valign="middle" >1.50</td></tr><tr><td align="center" valign="middle" >≥24</td><td align="center" valign="middle" >5.20</td><td align="center" valign="middle" >5.16</td><td align="center" valign="middle" >1.36</td><td align="center" valign="middle" >3.02</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" >0.783</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >0.489</td><td align="center" valign="middle" >0.051</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >临床分期</td><td align="center" valign="middle" >I</td><td align="center" valign="middle" >5.10</td><td align="center" valign="middle" >5.09</td><td align="center" valign="middle" >1.07</td><td align="center" valign="middle" >2.85</td><td align="center" valign="middle" >1.45</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >5.15</td><td align="center" valign="middle" >5.22</td><td align="center" valign="middle" >1.36</td><td align="center" valign="middle" >2.97</td><td align="center" valign="middle" >1.47</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >5.08</td><td align="center" valign="middle" >5.57</td><td align="center" valign="middle" >1.14</td><td align="center" valign="middle" >3.27</td><td align="center" valign="middle" >1.52</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" >5.14</td><td align="center" valign="middle" >5.32</td><td align="center" valign="middle" >1.65</td><td align="center" valign="middle" >2.94</td><td align="center" valign="middle" >1.47</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.557</td><td align="center" valign="middle" >0.453</td><td align="center" valign="middle" >0.073</td><td align="center" valign="middle" >0.324</td><td align="center" valign="middle" >0.978</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >组织学分型</td><td align="center" valign="middle" >浸润性导管癌</td><td align="center" valign="middle" >5.14</td><td align="center" valign="middle" >5.29</td><td align="center" valign="middle" >1.26</td><td align="center" valign="middle" >3.03</td><td align="center" valign="middle" >1.48</td></tr><tr><td align="center" valign="middle" >浸润性小叶癌</td><td align="center" valign="middle" >5.23</td><td align="center" valign="middle" >5.03</td><td align="center" valign="middle" >1.17</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >1.56</td></tr><tr><td align="center" valign="middle" >髓样癌</td><td align="center" valign="middle" >4.96</td><td align="center" valign="middle" >4.29</td><td align="center" valign="middle" >0.91</td><td align="center" valign="middle" >2.32</td><td align="center" valign="middle" >1.32</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >5.04</td><td align="center" valign="middle" >5.02</td><td align="center" valign="middle" >1.45</td><td align="center" valign="middle" >2.81</td><td align="center" valign="middle" >1.33</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.790</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.258</td><td align="center" valign="middle" >0.027</td><td align="center" valign="middle" >0.239</td></tr></tbody></table></table-wrap><p>表3. 化疗前临床病理学特征与中位血糖血脂水平的关系</p><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The relationship between clinicopathological characteristics and median blood glucose and blood lipid levels after chemotherap</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle" >临床特征</th><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >血糖</th><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle" >LDL</th><th align="center" valign="middle" >HDL</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >月经状态</td><td align="center" valign="middle" >未绝经</td><td align="center" valign="middle" >5.47</td><td align="center" valign="middle" >5.26</td><td align="center" valign="middle" >1.27</td><td align="center" valign="middle" >3.20</td><td align="center" valign="middle" >1.40</td></tr><tr><td align="center" valign="middle" >已绝经</td><td align="center" valign="middle" >5.76</td><td align="center" valign="middle" >5.83</td><td align="center" valign="middle" >1.39</td><td align="center" valign="middle" >3.47</td><td align="center" valign="middle" >1.44</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.063</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.334</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >体质指数</td><td align="center" valign="middle" >&lt;18.5</td><td align="center" valign="middle" >7.03</td><td align="center" valign="middle" >6.47</td><td align="center" valign="middle" >0.85</td><td align="center" valign="middle" >3.68</td><td align="center" valign="middle" >1.89</td></tr><tr><td align="center" valign="middle" >18.5~23.9</td><td align="center" valign="middle" >5.32</td><td align="center" valign="middle" >5.42</td><td align="center" valign="middle" >1.31</td><td align="center" valign="middle" >3.23</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >≥24</td><td align="center" valign="middle" >5.76</td><td align="center" valign="middle" >5.76</td><td align="center" valign="middle" >1.37</td><td align="center" valign="middle" >3.39</td><td align="center" valign="middle" >1.41</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >0.033</td><td align="center" valign="middle" >0.133</td><td align="center" valign="middle" >0.117</td><td align="center" valign="middle" >0.009</td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="5"  >临床分期</th><th align="center" valign="middle" >I</th><th align="center" valign="middle" >5.74</th><th align="center" valign="middle" >5.60</th><th align="center" valign="middle" >1.26</th><th align="center" valign="middle" >3.44</th><th align="center" valign="middle" >1.43</th></tr></thead><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >5.73</td><td align="center" valign="middle" >5.61</td><td align="center" valign="middle" >1.46</td><td align="center" valign="middle" >3.24</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >5.25</td><td align="center" valign="middle" >5.83</td><td align="center" valign="middle" >1.45</td><td align="center" valign="middle" >3.43</td><td align="center" valign="middle" >1.46</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" >5,29</td><td align="center" valign="middle" >5.00</td><td align="center" valign="middle" >0.96</td><td align="center" valign="middle" >2.97</td><td align="center" valign="middle" >1.35</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.418</td><td align="center" valign="middle" >0.735</td><td align="center" valign="middle" >0.174</td><td align="center" valign="middle" >0.464</td><td align="center" valign="middle" >0.875</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >组织学分型</td><td align="center" valign="middle" >浸润性导管癌</td><td align="center" valign="middle" >5.71</td><td align="center" valign="middle" >5.72</td><td align="center" valign="middle" >1.34</td><td align="center" valign="middle" >3.38</td><td align="center" valign="middle" >1.44</td></tr><tr><td align="center" valign="middle" >浸润性小叶癌</td><td align="center" valign="middle" >5.19</td><td align="center" valign="middle" >5.87</td><td align="center" valign="middle" >1.48</td><td align="center" valign="middle" >3.47</td><td align="center" valign="middle" >1.47</td></tr><tr><td align="center" valign="middle" >髓样癌</td><td align="center" valign="middle" >5.32</td><td align="center" valign="middle" >4.95</td><td align="center" valign="middle" >1.28</td><td align="center" valign="middle" >3.05</td><td align="center" valign="middle" >1.28</td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >5.75</td><td align="center" valign="middle" >5.20</td><td align="center" valign="middle" >1.34</td><td align="center" valign="middle" >3.00</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.325</td><td align="center" valign="middle" >0.028</td><td align="center" valign="middle" >0.779</td><td align="center" valign="middle" >0.092</td><td align="center" valign="middle" >0.657</td></tr></tbody></table></table-wrap></table-wrap-group><p>表4. 化疗后临床病理学特征与中位血糖血脂水平的关系</p><p>3) 化疗方式及化疗周期数对TNBC患者化疗前、后血液学检测指标的影响(表5)：接受辅助化疗的TNBC患者化疗前、后患者血糖、TC和LDL水平差异具有统计学意义(P &lt; 0.05)。接受新辅助化疗及姑息化疗的患者化疗前、后各项指标水平无差异(P &lt; 0.05)。化疗周期 ≤ 4周期的患者，除TG水平在化疗前、后存在差异外(P &lt; 0.05)，其余各项指标无差异。未观察到化疗周期数为4~8周期的患者化疗前、后各项检验指标存在差异。化疗周期数 ≥ 8周期的患者，化疗前、后血糖、TC和LDL水平存在差异(P &lt; 0.05)。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> The relationship between chemotherapy methods and cycles and the blood glucose and blood lipid levels of patients before and after chemotherap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >化疗方案及周期</th><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >血糖</th><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle" >LDL</th><th align="center" valign="middle" >HDL</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >新辅助</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.24</td><td align="center" valign="middle" >5.28</td><td align="center" valign="middle" >1.06</td><td align="center" valign="middle" >3.02</td><td align="center" valign="middle" >1.44</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.34</td><td align="center" valign="middle" >5.61</td><td align="center" valign="middle" >1.22</td><td align="center" valign="middle" >3.28</td><td align="center" valign="middle" >1.53</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.694</td><td align="center" valign="middle" >0.227</td><td align="center" valign="middle" >0.314</td><td align="center" valign="middle" >0.337</td><td align="center" valign="middle" >0.714</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >辅助</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.12</td><td align="center" valign="middle" >5.16</td><td align="center" valign="middle" >1.24</td><td align="center" valign="middle" >2.97</td><td align="center" valign="middle" >1.46</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.71</td><td align="center" valign="middle" >5.64</td><td align="center" valign="middle" >1.36</td><td align="center" valign="middle" >3.36</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.162</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.840</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >姑息</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.03</td><td align="center" valign="middle" >5.22</td><td align="center" valign="middle" >1.51</td><td align="center" valign="middle" >2.93</td><td align="center" valign="middle" >1.53</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.50</td><td align="center" valign="middle" >4.71</td><td align="center" valign="middle" >0.92</td><td align="center" valign="middle" >2.77</td><td align="center" valign="middle" >1.33</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.105</td><td align="center" valign="middle" >0.798</td><td align="center" valign="middle" >0.161</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.798</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >≤4周期</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.19</td><td align="center" valign="middle" >5.40</td><td align="center" valign="middle" >0.98</td><td align="center" valign="middle" >3.38</td><td align="center" valign="middle" >1.46</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.41</td><td align="center" valign="middle" >6.03</td><td align="center" valign="middle" >1.50</td><td align="center" valign="middle" >3.54</td><td align="center" valign="middle" >1.46</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.624</td><td align="center" valign="middle" >0.148</td><td align="center" valign="middle" >0.026</td><td align="center" valign="middle" >0.367</td><td align="center" valign="middle" >0.624</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >4~8周期</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.28</td><td align="center" valign="middle" >5.08</td><td align="center" valign="middle" >1.45</td><td align="center" valign="middle" >3.00</td><td align="center" valign="middle" >1.36</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.93</td><td align="center" valign="middle" >5.38</td><td align="center" valign="middle" >1.76</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >1.45</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >0.241</td><td align="center" valign="middle" >0.715</td><td align="center" valign="middle" >0.419</td><td align="center" valign="middle" >0.837</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >≥8周期</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.09</td><td align="center" valign="middle" >5.20</td><td align="center" valign="middle" >1.23</td><td align="center" valign="middle" >2.94</td><td align="center" valign="middle" >1.47</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.57</td><td align="center" valign="middle" >5.64</td><td align="center" valign="middle" >1.31</td><td align="center" valign="middle" >3.36</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >0.457</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.855</td></tr></tbody></table></table-wrap><p>表5. 化疗方式及周期数与患者化疗前、后血糖血脂水平的关系</p><p>4) 化疗方案对TNBC患者化疗前、后血液学检测指标的影响(表6)：接受FEC-T方案化疗的TNBC患者化疗前、后的中位血糖水平差异具有统计学意义(P &lt; 0.05)，其余各项指标差异无统计学意义(P &gt; 0.05)。接受AC-T方案化疗的TNBC患者，化疗前、后的中位血糖、TC和LDL水平差异具有统计学意义(P &lt; 0.05)。接受AT、TC、TAC和其他方案化疗的的患者化疗前、后各项检验指标水平差异均无统计学意义(P &lt; 0.05)。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> The relationship between chemotherapy regimens and patients’ median blood glucose and lipid levels before and after chemotherap</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >化疗方案</th><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >血糖</th><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle" >LDL</th><th align="center" valign="middle" >HDL</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >AT</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >4.75</td><td align="center" valign="middle" >5.11</td><td align="center" valign="middle" >0.97</td><td align="center" valign="middle" >2.76</td><td align="center" valign="middle" >1.57</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.04</td><td align="center" valign="middle" >4.96</td><td align="center" valign="middle" >1.08</td><td align="center" valign="middle" >3.25</td><td align="center" valign="middle" >1.55</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.259</td><td align="center" valign="middle" >0.620</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >0.165</td><td align="center" valign="middle" >0.902</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >FEC-T</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.19</td><td align="center" valign="middle" >5.02</td><td align="center" valign="middle" >1.40</td><td align="center" valign="middle" >2.60</td><td align="center" valign="middle" >1.52</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >6.04</td><td align="center" valign="middle" >5.66</td><td align="center" valign="middle" >1.61</td><td align="center" valign="middle" >3.35</td><td align="center" valign="middle" >1.46</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.029</td><td align="center" valign="middle" >0.468</td><td align="center" valign="middle" >0.956</td><td align="center" valign="middle" >0.423</td><td align="center" valign="middle" >0.724</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >AC-T</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.11</td><td align="center" valign="middle" >5.21</td><td align="center" valign="middle" >1.22</td><td align="center" valign="middle" >2.96</td><td align="center" valign="middle" >1.47</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.59</td><td align="center" valign="middle" >5.68</td><td align="center" valign="middle" >1.34</td><td align="center" valign="middle" >3.36</td><td align="center" valign="middle" >1.43</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >0.349</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.770</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >TC</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.31</td><td align="center" valign="middle" >5.18</td><td align="center" valign="middle" >1.04</td><td align="center" valign="middle" >3.35</td><td align="center" valign="middle" >1.35</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.41</td><td align="center" valign="middle" >6.03</td><td align="center" valign="middle" >1.50</td><td align="center" valign="middle" >3.52</td><td align="center" valign="middle" >1.42</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.724</td><td align="center" valign="middle" >0.204</td><td align="center" valign="middle" >0.072</td><td align="center" valign="middle" >0.614</td><td align="center" valign="middle" >0.801</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >TAC</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.34</td><td align="center" valign="middle" >5.34</td><td align="center" valign="middle" >2.08</td><td align="center" valign="middle" >3.00</td><td align="center" valign="middle" >1.31</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.74</td><td align="center" valign="middle" >5.38</td><td align="center" valign="middle" >2.55</td><td align="center" valign="middle" >3.23</td><td align="center" valign="middle" >1.26</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.438</td><td align="center" valign="middle" >0.652</td><td align="center" valign="middle" >0.438</td><td align="center" valign="middle" >0.748</td><td align="center" valign="middle" >0.699</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >其他</td><td align="center" valign="middle" >化疗前</td><td align="center" valign="middle" >5.13</td><td align="center" valign="middle" >5.15</td><td align="center" valign="middle" >0.95</td><td align="center" valign="middle" >3.12</td><td align="center" valign="middle" >1.45</td></tr><tr><td align="center" valign="middle" >化疗后</td><td align="center" valign="middle" >5.79</td><td align="center" valign="middle" >5.17</td><td align="center" valign="middle" >1.32</td><td align="center" valign="middle" >3.06</td><td align="center" valign="middle" >1.47</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >0.076</td><td align="center" valign="middle" >0.748</td><td align="center" valign="middle" >0.519</td><td align="center" valign="middle" >0.478</td><td align="center" valign="middle" >0.519</td></tr></tbody></table></table-wrap><p>表6. 化疗方案与患者化疗前、后中位血糖血脂水平的关系</p></sec><sec id="s8"><title>4. 讨论</title><p>目前在世界范围内，女性乳腺癌被认为是仅次于肺癌的第二大癌症死亡原因 [<xref ref-type="bibr" rid="hanspub.39433-ref15">15</xref>]，而心血管系统疾病的发病率和死亡率高居榜首，乳腺癌和心血管疾病一起严重威胁女性的生命健康安全 [<xref ref-type="bibr" rid="hanspub.39433-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref17">17</xref>]。血糖、高胆固醇和高LDL水平作为独立的危险因素，能显著增加心血管系统疾病患病风险 [<xref ref-type="bibr" rid="hanspub.39433-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref21">21</xref>]，既往有研究报道，乳腺癌患者在接受化疗后，罹患心血管系统疾病的风险也明显升高 [<xref ref-type="bibr" rid="hanspub.39433-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref24">24</xref>]。与以往研究相符，本研究结果显示TNBC患者化疗后，患者的血糖、血脂代谢水平均明显升高，提示化疗对TNBC患者的血糖血脂代谢产生了一定的影响。但也有研究指出，化疗引起的血糖、血脂代谢紊乱是暂时性的，化疗停止一段时间后，患者的血糖、血脂水平基本恢复到了基线水平 [<xref ref-type="bibr" rid="hanspub.39433-ref25">25</xref>]。与LDL对心血管系统的影响不同，HDL作为心血管系统重要的保护因素而存在 [<xref ref-type="bibr" rid="hanspub.39433-ref26">26</xref>]，目前化疗对HDL代谢水平的影响尚无定论。在本研究中，未观察到化疗前、后HDL代谢水平存在差异。因本次入选患者绝大多数为接受蒽环类为基础的联合化疗方案，因此不同于直接损伤心肌细胞的机制，化疗药物能否通过影响TNBC患者的血糖、血脂代谢，进而增加罹患心血管系统疾病的风险，目前仍不明确。</p><p>不同的化疗方式和化疗方案，对患者的血糖、血脂代谢水平产生的影响不尽相同。经辅助化疗方式治疗的TNBC患者，化疗后血糖、血脂中位代谢水平较化疗前明显升高，而新辅助化疗组中未观察到代谢水平差异。接受AT、TC、TAC和其他化疗方案化疗的患者，化疗前、后各项代谢指标未观察到差异。而接受AC-T方案治疗的患者，化疗前、后血糖、血脂和LDL-C代谢水平均明显升高。同时，本研究的还发现，长周期化疗的患者化疗前、后血糖血脂水平出现差异，而短周期化疗的患者未显示出这种差异。接受长化疗周期数化疗的患者，发生血糖血脂代谢紊乱的可能性也在增加。这提示我们，根据患者的临床特点，合理选择化疗方式和化疗方案，对降低患者发生血糖血脂代谢紊乱的可能性，可能会有一定帮助，但这显然需要更多临床数据支持。</p><p>近年来，以免疫检查点抑制剂为代表的免疫治疗在晚期乳腺癌治疗的临床研究中取得了良好的疗效 [<xref ref-type="bibr" rid="hanspub.39433-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.39433-ref29">29</xref>]。免疫治疗关键问题是选择合适的人群和治疗方式，TNBC具有独特的分子病理特征，很可能是免疫治疗潜在的获益人群 [<xref ref-type="bibr" rid="hanspub.39433-ref3">3</xref>]。目前，许多临床试验正在进行，以探索联合应用化疗药物和免疫检查点抑制剂治疗TBNC的可行性，但联合用药对心血管系统的潜在风险，尤其是蒽环类药物和免疫检查点抑制剂的严重心脏毒性，值得我们警惕 [<xref ref-type="bibr" rid="hanspub.39433-ref30">30</xref>]。因此，探究抗肿瘤药物对心血管系统的影响，深入了解抗肿瘤药物与心血管系统疾病之间的关系，并探究其中的机制，对加深抗肿瘤治疗与心血管防治领域的联系，意义重大。</p></sec><sec id="s9"><title>文章引用</title><p>臧龙龙,程敬敬,姜 韬,张红军. 三阴性乳腺癌患者化疗后血糖血脂代谢状况及其影响因素的分析The Metabolism of Blood Glucose and Lipid and Its Influence Factors Analysis in Triple-Negative Breast Cancer Patients after Chemotherapy[J]. 临床医学进展, 2020, 10(12): 3142-3150. https://doi.org/10.12677/ACM.2020.1012470</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39433-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Azim, H.A., Ghosn, M., Oualla, K., et al. (2020) Personalized Treatment in Metastatic Triple-Negative Breast Cancer: The Outlook in 2020. The Breast Journal, 26, 69-80. https://doi.org/10.1111/tbj.13713</mixed-citation></ref><ref id="hanspub.39433-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, P. and Aggarwal, R. (2016) An Overview of Triple-Negative Breast Cancer. Archives of Gynecology and Obstetrics, 293, 247-269. https://doi.org/10.1007/s00404-015-3859-y</mixed-citation></ref><ref id="hanspub.39433-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Da Silva, J.L., Cardoso Nunes, N.C., Izetti, P., et al. (2020) Triple Negative Breast Cancer: A Thorough Review of Biomarkers. Critical Reviews in Oncology/Hematology, 145, Article ID: 102855.  
https://doi.org/10.1016/j.critrevonc.2019.102855</mixed-citation></ref><ref id="hanspub.39433-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yang, C.-Q., et al. (2020) Recent Treatment Progress of Triple Negative Breast Cancer. Progress in Biophysics and Molecular Biology, 151, 40-53. https://doi.org/10.1016/j.pbiomolbio.2019.11.007</mixed-citation></ref><ref id="hanspub.39433-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Santuario-Facio, S.K., Cardona-Huerta, S., Perez-Paramo, Y.X., et al. (2017) A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy. Molecular Medicine, 23, 101-111. https://doi.org/10.2119/molmed.2016.00257</mixed-citation></ref><ref id="hanspub.39433-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Abdel-Qadir, H., Austin, P.C., Lee, D.S., et al. (2017) A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiology, 2, 88-93. https://doi.org/10.1001/jamacardio.2016.3841</mixed-citation></ref><ref id="hanspub.39433-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Meijers, W.C. and De Boer, R.A. (2019) Common Risk Factors for Heart Failure and Cancer. Cardiovascular Research, 115, 844-853. https://doi.org/10.1093/cvr/cvz035</mixed-citation></ref><ref id="hanspub.39433-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dieli-Conwright, C.M., Wong, L., Waliany, S., et al. (2016) An Observational Study to Examine Changes in Metabolic Syndrome Components in Patients with Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy. Cancer, 122, 2646-2653. https://doi.org/10.1002/cncr.30104</mixed-citation></ref><ref id="hanspub.39433-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, M., Tuaine, J., Mclaren, B., et al. (2016) Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLoS ONE, 11, e0148049.  
https://doi.org/10.1371/journal.pone.0148049</mixed-citation></ref><ref id="hanspub.39433-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Srokowski, T.P., Fang, S., Hortobagyi, G.N., et al. (2009) Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients with Breast Cancer. Journal of Clinical Oncology, 27, 2170-2176.  
https://doi.org/10.1200/JCO.2008.17.5935</mixed-citation></ref><ref id="hanspub.39433-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Giuliano, A.E., Connolly, J.L., Edge, S.B., et al. (2017) Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA: A Cancer Journal for Clinicians, 67, 290-303.  
https://doi.org/10.3322/caac.21393</mixed-citation></ref><ref id="hanspub.39433-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">中国抗癌协会乳腺癌诊治指南与规范(2019年版) [J]. 中国癌症杂志, 2019, 29(8): 609-680.</mixed-citation></ref><ref id="hanspub.39433-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">池胜英, 袁谦, 陈筱菲, 等. 医院内快速血糖检测质量管理的实施[J]. 中华检验医学杂志, 2006, 29(6): 565-566.</mixed-citation></ref><ref id="hanspub.39433-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">向哲邑, 吴佳丽, 胡敏. 临床实验室的血脂检测与管理[J]. 中华检验医学杂志, 2017, 40(6): 421-424.</mixed-citation></ref><ref id="hanspub.39433-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ghoncheh, M., Pournamdar, Z. and Salehiniya, H. (2016) Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific Journal of Cancer Prevention: APJCP, 17, 43-46.  
https://doi.org/10.7314/APJCP.2016.17.S3.43</mixed-citation></ref><ref id="hanspub.39433-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">师金, 梁迪, 李道娟, 等. 全球女性乳腺癌流行情况研究[J]. 中国肿瘤, 2017, 26(9): 683-690.</mixed-citation></ref><ref id="hanspub.39433-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gerdts, E. and Regitz-Zagrosek, V. (2019) Sex Differences in Cardiometabolic Disorders. Nature Medicine, 25, 1657-1666. https://doi.org/10.1038/s41591-019-0643-8</mixed-citation></ref><ref id="hanspub.39433-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9): 833-854.</mixed-citation></ref><ref id="hanspub.39433-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chase-Vilchez, A.Z., Chan, I.H.Y., Peters, S.A.E., et al. (2020) Diabetes as a Risk Factor for Incident Peripheral Arterial Disease in Women Compared to Men: A Systematic Review and Meta-Analysis. Cardiovascular Diabetology, 19, 151. https://doi.org/10.1186/s12933-020-01130-4</mixed-citation></ref><ref id="hanspub.39433-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X., Liu, J., Wang, M., et al. (2018) Twenty-Year Epidemiologic Study on LDL-C Levels in Relation to the Risks of Atherosclerotic Event, Hemorrhagic Stroke, and Cancer Death among Young and Middle-Aged Population in China. Journal of Clinical Lipidology, 12, 1179-1189e4. https://doi.org/10.1016/j.jacl.2018.06.011</mixed-citation></ref><ref id="hanspub.39433-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Michels, N., De Backer, F., Dimakopoulou, M., et al. (2020) Eating Disorders and the Risk of Developing Cancer: A Systematic Review. Eating and Weight Disorders: EWD. https://doi.org/10.1007/s40519-020-01020-4</mixed-citation></ref><ref id="hanspub.39433-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chung, I.Y., Lee, J.W., Moon, H.G., et al. (2020) Effect of Standard Low-Dose Anthracycline Chemotherapy on Late Congestive Heart Failure in Breast Cancer Survivors Aged between 50 and 59 at Diagnosis: A Nationwide Study. Breast, 53, 125-129. https://doi.org/10.1016/j.breast.2020.07.006</mixed-citation></ref><ref id="hanspub.39433-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Jacobse, J.N., Schaapveld, M., Boekel, N.B., et al. (2020) Risk of Heart Failure after Systemic Treatment for Early Breast Cancer: Results of a Cohort Study. Breast Cancer Research and Treatment.  
https://doi.org/10.1007/s10549-020-05930-w</mixed-citation></ref><ref id="hanspub.39433-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cho, H., Lee, S., Sim, S.H., et al. (2020) Cumulative Incidence of Chemotherapy-Induced Cardiotoxicity during a 2-Year Follow-Up Period in Breast Cancer Patients. Breast Cancer Research and Treatment, 182, 333-343.  
https://doi.org/10.1007/s10549-020-05703-5</mixed-citation></ref><ref id="hanspub.39433-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Tian, W., Yao, Y., Fan, G., et al. (2019) Changes in Lipid Profiles during and after (neo)Adjuvant Chemotherapy in Women with Early-Stage Breast Cancer: A Retrospective Study. PLoS ONE, 14, e0221866.  
https://doi.org/10.1371/journal.pone.0221866</mixed-citation></ref><ref id="hanspub.39433-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Rader, D.J. and Hovingh, G.K. (2014) HDL and Cardiovascular Disease. The Lancet, 384, 618-625.  
https://doi.org/10.1016/S0140-6736(14)61217-4</mixed-citation></ref><ref id="hanspub.39433-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">De Melo Gagliato, D., Buzaid, A.C., Perez-Garcia, J., et al. (2020) Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 34, 611-623.  
https://doi.org/10.1007/s40259-020-00436-9</mixed-citation></ref><ref id="hanspub.39433-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mittendorf, E.A., Zhang, H., Barrios, C.H., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy versus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100. https://doi.org/10.1016/S0140-6736(20)31953-X</mixed-citation></ref><ref id="hanspub.39433-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Schmid, P., Cortes, J., Pusztai, L., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 382, 810-821. https://doi.org/10.1056/NEJMoa1910549</mixed-citation></ref><ref id="hanspub.39433-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Khan, S. and Gerber, D.E. (2020) Autoimmunity, Checkpoint Inhibitor Therapy and Immune-Related Adverse Events: A Review. Seminars in Cancer Biology, 64, 93-101. https://doi.org/10.1016/j.semcancer.2019.06.012</mixed-citation></ref></ref-list></back></article>